Flamm B L, Anton D, Goings J R, Newman J
Department of Obstetrics and Gynecology, Kaiser Permanente Medical Centers, Los Angeles, Riverside, CA 92505, USA.
Am J Perinatol. 1997 Mar;14(3):157-60. doi: 10.1055/s-2007-994118.
To evaluate the maternal and fetal outcomes of a large cohort of women treated with prostaglandin E2 (PGE2) gel for cervical ripening prior to trial of labor after previous cesarean delivery. Beginning in 1990 all pregnant patients with previous cesarean delivery presenting for prenatal care at 10 California hospitals were prospectively studied. We analyzed multiple parameters to compare outcomes of cases in which PGE2 gel was used to outcomes in a control group in which PGE2 was not used. Data were examined by X2 testing. During the study period 5022 patients underwent trial of labor after prior cesarean delivery. Of these 5022 patients, 453 (9%) were treated with PGE2 gel. There was no significant difference in the incidence of uterine rupture between the PGE2 group and the control group. Indicators of maternal and perinatal morbidity were not significantly higher in the prostaglandin treated group. The use of PGE2 gel for cervical ripening appears to be relatively safe in patients with prior cesarean delivery.
评估一大群既往剖宫产术后在引产试验前接受前列腺素E2（PGE2）凝胶促宫颈成熟治疗的女性的母胎结局。从1990年开始，对加利福尼亚州10家医院所有前来接受产前检查的既往剖宫产术后孕妇进行前瞻性研究。我们分析了多个参数，以比较使用PGE2凝胶的病例与未使用PGE2的对照组的结局。数据通过X2检验进行分析。在研究期间，5022例患者在既往剖宫产术后接受了引产试验。在这5022例患者中，453例（9%）接受了PGE2凝胶治疗。PGE2组与对照组之间子宫破裂的发生率无显著差异。前列腺素治疗组的孕产妇和围产期发病率指标也没有显著升高。对于既往剖宫产术后的患者，使用PGE2凝胶促宫颈成熟似乎相对安全。
